No Data
Promising Clinical Trials and Potential Functional Cure Drive Buy Rating for Barinthus Biotherapeutics
ADRs End Lower; Barinthus Biotherapeutics PLC Declines 30%
Barinthus Biotherapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Phase 2b HBV003 Clinical Trial.
Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results
Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
Arbutus And Barinthus Bio Report IM-PROVE II Trial Data Showing Nivolumab Boosts HBsAg Loss Rates In Chronic Hepatitis B Patients; 23% Achieve HBsAg Loss By Week 48 With Imdusiran, VTP-300, And Low-Dose Nivolumab
No Data
No Data